IKT compared with LONA: revenue, margins and what each company keeps, and the suppliers and customers both name

IKTInhibikase Therapeutics, Inc.

Mkt capRevenueRevenue

LONALeonaBio, Inc.

Mkt capRevenueRevenue

Compare

IKTInhibikase Therapeutics, Inc.

LONALeonaBio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IKT

Reportimpliedrealized× implied

Q2 FY26—▼−2.04%—

May 13 '26—▼−1.04%—

Q1 FY26—▲+3.07%—

Q3 FY25—▼−0.65%—

LONA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−3.20%—

= impliedIKT realized, solidLONA realized, hatchedOne scale, both sides: full bar = 4%× = |realized| ÷ impliedSource: market data

IKTInhibikase Therapeutics, Inc.

1.50▲+4.05%· post 1.50

Mkt cap$209.3MRevenue$79,569Q3 FY23

LONALeonaBio, Inc.

4.45▲+2.53%· post 4.45

ClosedNov 6 '26

Mkt cap$41.6MRevenue—

Compare

ClosedNov 6 '26

IKTInhibikase Therapeutics, Inc.

LONALeonaBio, Inc.

1.50▲+4.05%post 1.50

Price

4.45▲+2.53%post 4.45

$209.3M

Mkt cap

$41.6M

Q3 FY23$79,569

Revenue

—

IKT1.50▲+4.05%vsLONA4.45▲+2.53%ClosedNov 6 '26